Properties (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
acquired_by_Lundbeck
|
| gptkbp:businessModel |
focused on specialty pharmaceuticals
focuses on business development initiatives |
| gptkbp:CEO |
gptkb:Mark_J._Litton
|
| gptkbp:clinicalTrials |
ongoing clinical trials
conducts clinical research studies aims to improve clinical outcomes for patients published clinical data in medical journals Phase 3 trials for Eptinezumab aims to enhance patient outcomes chronic migraine prevention designs clinical trial protocols involved in drug development processes manages multiple clinical trial phases preventive treatment for chronic migraine reports clinical trial results conducts_Phase_1,_2,_and_3_trials |
| gptkbp:community_service |
educates healthcare professionals
|
| gptkbp:communityEngagement |
engages with the medical community
|
| gptkbp:communityPartnerships |
establishes healthcare partnerships
|
| gptkbp:drugInterdiction |
receives_drug_approvals_from_FDA
|
| gptkbp:employeeCount |
approximately 100
|
| gptkbp:financialPerformance |
holds patents for drug formulations
|
| gptkbp:financials |
publishes financial reports quarterly
|
| gptkbp:focus |
development of therapies for migraine
|
| gptkbp:founded |
2004
|
| gptkbp:founder |
gptkb:Randall_C._Schatzman
|
| gptkbp:hasCapacity |
provides patient support programs
|
| gptkbp:hasPrograms |
comprised of industry experts
|
| gptkbp:hasResearchInterest |
conducts market research for product development
|
| gptkbp:headquarters |
gptkb:Bothell,_Washington
|
| gptkbp:healthcare |
provides patient education resources
|
| gptkbp:historicalResearch |
engages in collaborative research efforts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alder BioPharmaceuticals
|
| gptkbp:investmentFocus |
institutional investors
maintains investor relations program secured funding from venture capital |
| gptkbp:leads |
Eptinezumab (brand name Vyepti)
|
| gptkbp:market |
neurology
analyzes market trends in biotechnology launched_Eptinezumab_in_2020 |
| gptkbp:marketSegment |
works on market access strategies
develops market strategies for products |
| gptkbp:partnerships |
formed strategic partnerships
collaborated with AbbVie |
| gptkbp:products |
gptkb:Eptinezumab
focus on innovative therapies |
| gptkbp:regulatoryCompliance |
ensures regulatory compliance
submissions to regulatory agencies FDA_approval_for_Eptinezumab |
| gptkbp:research |
receives research funding from grants
|
| gptkbp:research_areas |
pain management
drives therapeutic innovation in migraine treatment |
| gptkbp:researchAreas |
monoclonal antibodies
|
| gptkbp:researchInterest |
collaborated with academic institutions
publishes scientific publications |
| gptkbp:revenue |
reported revenue in 2020
|
| gptkbp:stockSymbol |
ALDR
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple drug candidates in development
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.alderbio.com
|